Karyopharm Therapeutics Inc.

KPTI Healthcare Biotechnology

Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024.

Revenue
−11.9%
EPS
+46.3%
Free cash flow
−33.3%
Total debt
+36.6%

Quarter to June 2026, against a year earlier

0.05 0.01 −16.67%
Market cap
$1.4M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
−23.89
Beneish M
−8.05
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
78.98% 82.70% 81.86% 58.11%

+8 more TTM periods

Piotroski F-Score
2 2 3 3
ROA
(207.90%) (150.48%) (143.71%) (87.24%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
809.55% (2,137.35%) (1,751.91%) (4,596.86%)
Average Days of Receivables
74.36 56.41 65.42 81.63
Free Cash Flow per Share
(2.26) (2.69) (6.89) (10.31)
Free Cash Flow
(65.35) (59.11) (75.37) (89.35)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026